| Sean C Dowdy, MD | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Sean C Dowdy |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 27 Years |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134109630 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 40913 (Minnesota) | Primary |
| 207VX0201X | Obstetrics & Gynecology - Gynecologic Oncology | 40913 (Minnesota) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospital Rochester | Rochester, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic | 6507778255 | 4232 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of intent to grant for a patent in the Kreutzer-Limmer III patent series (EP Application No 02702247.4). This patent series stems from the pioneering RNAi research performed by scientists at Ribopharma AG, which was acquired by Alnylam in 2003.
Heart failure hospitalizations and costs related to methamphetamine use jumped sharply over a decade in California, according to new research published today in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
Researchers at Indiana University School of Medicine have taken a step toward understanding the genetics that make people more susceptible to the loss of hearing as they age.
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
New Penn Medicine research has found that elevated levels in the blood of the brain-enriched protein calpain-cleaved αII-spectrin N-terminal fragment, known as SNTF, shortly after sports-related concussion can predict the severity of post-concussion symptoms in professional athletes.
› Verified 3 days ago
| Entity Name | Mayo Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of intent to grant for a patent in the Kreutzer-Limmer III patent series (EP Application No 02702247.4). This patent series stems from the pioneering RNAi research performed by scientists at Ribopharma AG, which was acquired by Alnylam in 2003.
Heart failure hospitalizations and costs related to methamphetamine use jumped sharply over a decade in California, according to new research published today in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
Researchers at Indiana University School of Medicine have taken a step toward understanding the genetics that make people more susceptible to the loss of hearing as they age.
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
New Penn Medicine research has found that elevated levels in the blood of the brain-enriched protein calpain-cleaved αII-spectrin N-terminal fragment, known as SNTF, shortly after sports-related concussion can predict the severity of post-concussion symptoms in professional athletes.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sean C Dowdy, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Sean C Dowdy, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of intent to grant for a patent in the Kreutzer-Limmer III patent series (EP Application No 02702247.4). This patent series stems from the pioneering RNAi research performed by scientists at Ribopharma AG, which was acquired by Alnylam in 2003.
Heart failure hospitalizations and costs related to methamphetamine use jumped sharply over a decade in California, according to new research published today in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
Researchers at Indiana University School of Medicine have taken a step toward understanding the genetics that make people more susceptible to the loss of hearing as they age.
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
New Penn Medicine research has found that elevated levels in the blood of the brain-enriched protein calpain-cleaved αII-spectrin N-terminal fragment, known as SNTF, shortly after sports-related concussion can predict the severity of post-concussion symptoms in professional athletes.
› Verified 3 days ago
Nancy Cole Nelson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Brandon Paul Maddy, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Janelle Santos, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Priyal Praful Fadadu, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Jack F Perrone, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1650 4th St Se, Rochester, MN 55904 Phone: 507-288-3443 | |
Vanessa E Torbenson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Luis F Suarez, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |